“Real-World Effectiveness of Up to 12-Month Tralokinumab Treatment in Adults With Atopic Dermatitis Who Previously Discontinued Dupilumab or Janus Kinase Inhibitors”, J of Skin, vol. 10, no. 2, p. s728, Mar. 2026, doi: 10.25251/wx06pe13.